K202573 is an FDA 510(k) clearance for the LIAISON Lyme IgM, LIAISON Lyme IgM Control Set, LIAISON Lyme Total Antibody Plus. Classified as Reagent, Borrelia Serological Reagent (product code LSR), Class II - Special Controls.
Submitted by DiaSorin, Inc. (Stillwater, US). The FDA issued a Cleared decision on February 18, 2021 after a review of 167 days - an extended review cycle.
This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.3830 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Microbiology review framework, consistent with the majority of Class II 510(k) submissions.
View all DiaSorin, Inc. devices